Fulvestrant ('Faslodex'): extending the reach of endocrine therapy?
An effective option for estrogen receptor-positive breast cancer, endocrine therapy has had a significant role in improving the survival of women with postmenopausal breast cancer for more than 20 years. However, acquired resistance to disease by cancer cells is the repeated cause of relapse for patients. This supplement explores current thinking on resistance to endocrine therapy and, in particular, the potential role for fulvestrant ('Faslodex'), a novel endocrine therapy that possesses a unique mechanism of action.